916258-24-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate is used as a building block for the synthesis of bioactive molecules and pharmaceuticals. Its unique structure and properties contribute to the development of new drugs and therapeutics, enhancing the discovery and creation of novel treatments for various diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate serves as a versatile intermediate for the preparation of a wide range of organic compounds. Its reactivity and functional groups allow for various chemical transformations, enabling the synthesis of complex molecules with potential applications in different industries.
Used in Chemical Biology:
Tert-butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate is also used in chemical biology for the study of biological processes and the development of bioactive compounds. Its unique structure allows for the exploration of novel interactions with biological targets, potentially leading to the discovery of new therapeutic agents and a better understanding of biological systems.

InChI:InChI=1S/C12H14BrN3O2/c1-7-9-5-8(13)6-14-10(9)16(15-7)11(17)18-12(2,3)4/h5-6H,1-4H3

Upstream product

• 1111637-94-5 5-bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1111637-73-0 1-(5-bromo-2-fluoropyridin-3-yl)ethanol 
• 875781-15-0 5-bromo-2-fluoro-3-pyridinecarboxaldehyde 
• 1111637-74-1 1-(5-bromo-2-fluoropyridin-3-yl)ethanone 
• 885223-65-4 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine 

Downstream Products

• 916258-26-9 tert-butyl 5-bromo-3-(bromomethyl)-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 

Relevant academic research and scientific papers

HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, tautomer, isotope, or salt thereof, wherein A, X, R3, R5, R6, R7, R8, Y

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer

A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast

NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is -NR3R4 or -OR5; R2 is selected from aryl, heteroaryl, fused aryl- heterocycloalkyl and fused heteroaryl-heterocycloalkyl each of which may be optionally substituted by one or more R8 groups; R3 is H or alkyl; R4 is: (i) cycloalkyl optionally substituted by one or more -NR11R12, -NHCO2R11, -NHCOR11 and -NHSO2R11 groups; or (ii) -(CH2)n-heterocycloalkyl, wherein said heterocycloalkyl is a 4, 5 or 6-membered nitrogen-containing group optionally containing one or more CO groups, wherein said heterocycloalkyl is optionally substituted by one or more one or more (CH2)nR7 groups; (iii) -(CH2)n-heteroaryl, wherein said heteroaryl group is optionally substituted by one or more R7 groups; or (iv) alkyl substituted by one or more -NR11R12groups; or R3 and R4 are linked together with the nitrogen to which they are attached to form a 4, 5 or 6-membered heterocycloalkyl group optionally containing one or two further groups selected from CO, O, N and S, and which is optionally further substituted by one or more R7 groups; R5 is selected from alkyl, -(CH2)n-heteroaryl and -(CH2)n-heterocycloalkyl, wherein said heteroaryl and heterocycloalkyl groups are each optionally substituted by one or more R7 groups; each R11 and R12 is independently H or alkyl; and each n is independently an integer from O to 6; for use in treating or preventing a disorder associated with CDPK. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of PfCDPK1.

2-OXO-1-PYRROLIDINE DERIVATIVES

The present invention concerns 2-oxo-1 -pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.